This HTML5 document contains 72 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n17http://dbpedia.org/resource/HER2/
n14https://global.dbpedia.org/id/
yagohttp://dbpedia.org/class/yago/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
freebasehttp://rdf.freebase.com/ns/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbchttp://dbpedia.org/resource/Category:
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
goldhttp://purl.org/linguistics/gold/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Neuvenge
rdf:type
yago:Immunogen103562739 yago:Vaccine104517535 yago:WikicatCancerVaccines dbo:Drug yago:Matter100020827 yago:PhysicalEntity100001930 yago:Antigen115037339 yago:Substance100020090
rdfs:label
Neuvenge
rdfs:comment
Neuvenge, Lapuleucel-T (APC 8024), is a therapeutic cancer vaccine (TCV) in development (clinical trial) by Dendreon (DNDN). It uses the "immunotherapy platform approach" first successfully demonstrated on the U.S. Food and Drug Administration (FDA)-approved TCV Provenge. It was first tested on breast cancer patients with tumors expressing HER2/neu, and is now scheduled to be tested on bladder cancer patients.
dcterms:subject
dbc:Cancer_vaccines
dbo:wikiPageID
30045028
dbo:wikiPageRevisionID
1103788038
dbo:wikiPageWikiLink
dbr:Provenge dbr:Atlanta,_Georgia dbr:Los_Angeles_County,_California dbr:GM-CSF dbr:Philadelphia_(film) dbr:Oncologist dbr:Monotherapy dbr:Oncogene dbr:Penile dbc:Cancer_vaccines dbr:Adjuvant dbr:Cancer_vaccine dbr:Cytotoxic dbr:Vulvar_cancer dbr:Chemotherapy dbr:Opportunistic_infections dbr:Human_herpesvirus_8 dbr:Seal_Beach,_California dbr:Karposi's_sarcoma dbr:Sex_steroids dbr:AIDS dbr:Cervical_cancer dbr:CD64_(biology) dbr:HPV dbr:HPV-positive_oropharyngeal_cancer dbr:Epidermal_growth_factor_receptor dbr:Immunotherapy dbr:Apoptosis dbr:Castration-resistant_prostate_cancer dbr:Food_and_Drug_Administration dbr:Bladder_cancer dbr:Morris_Plains,_New_Jersey dbr:Breast_cancer dbr:Tuberculosis dbr:CD8 n17:neu dbr:Vaginal dbr:Antigen_presenting_cells dbr:Coley's_Toxins dbr:Prostate_cancer dbr:Anal_cancer dbr:Orange_County,_California dbr:Clinical_trial dbr:Mass_production dbr:Dendreon dbr:Hepatitis_B_virus
owl:sameAs
yago-res:Neuvenge n14:4sTj8 wikidata:Q7003154 freebase:m.0g59796
dbp:wikiPageUsesTemplate
dbt:Citation_needed dbt:Reflist dbt:Short_description dbt:Unreliable_medical_source
dbo:abstract
Neuvenge, Lapuleucel-T (APC 8024), is a therapeutic cancer vaccine (TCV) in development (clinical trial) by Dendreon (DNDN). It uses the "immunotherapy platform approach" first successfully demonstrated on the U.S. Food and Drug Administration (FDA)-approved TCV Provenge. It was first tested on breast cancer patients with tumors expressing HER2/neu, and is now scheduled to be tested on bladder cancer patients.
gold:hypernym
dbr:Vaccine
prov:wasDerivedFrom
wikipedia-en:Neuvenge?oldid=1103788038&ns=0
dbo:wikiPageLength
9846
foaf:isPrimaryTopicOf
wikipedia-en:Neuvenge